Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for early breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study

Archives of Medical Science, 05/10/2012

One out of five treated patients discontinues trastuzumab in an adjuvant setting due to cardiac complications. LV dysfunction is the most frequent. Routine cardiac monitoring should be obligatory.

Print Article Summary Cat 2 CME Report